REGULATORY

• MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
  November 18, 2016

• MOF Panel Budget Recommendation Calls for Curbing Drug Costs
  November 18, 2016

• 10 APIs/17 Products to Join NHI Price List on Nov. 18
  November 17, 2016

• Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
  November 17, 2016

• Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
  November 17, 2016

• 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
  November 17, 2016

• ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
  November 16, 2016

• 3 Immunosuppressants to Be Discussed for Lifting of Contraindicated Pregnancy Use
  November 16, 2016

• Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
  November 15, 2016

• MHLW Advisory Committee to Review Biogen’s MS Drug on Nov. 25
  November 14, 2016

• Opdivo Gets MHLW Panel Nod for Hodgkin’s Lymphoma
  November 14, 2016

• MHLW Panel to Discuss NSCLC Indication for Keytruda on Nov. 24
  November 14, 2016

• LDP Study Group on Biologics to Hold 1st Meeting on Nov. 24; Aims to Halt the Rush to Promote Biosimilars
  November 11, 2016

• Chuikyo Members Chide Unexplained Withdrawal of Taltz’s Listing Request
  November 10, 2016

• MHLW Won’t Require Use of Other Psoriasis Drugs before Taltz
  November 10, 2016

• MHLW Plans 50% Price Cut for Opdivo
  November 10, 2016

• Chuikyo OKs Taltz, Micatrio for Listing on Nov. 18; Keytruda Takes Pass This Time
  November 9, 2016

• LDP Lawmakers Discuss Re-Pricing of Opdivo; Some Say Application of Huge Seller Rule Reasonable
  November 9, 2016

• Shiozaki Lauds BIKEN-Mitsubishi Vaccine JV
  November 8, 2016

• PMDA Fastest in Granting New Drug Approvals
  November 4, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 267
• 268
• 269
• 270
• 271
• 272
• 273
• 274
• 275
• …
• Next ›
• 最終 »